Literature DB >> 25521405

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

Matthew D Hellmann1, Boris Reva, Helena Yu, Valerie W Rusch, Naiyer A Rizvi, Mark G Kris, Maria E Arcila.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25521405      PMCID： PMC4655969          DOI： 10.1097/JTO.0000000000000221

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

Authors:  Katsuhiro Masago; Shiro Fujita; Kaoru Irisa; Yung Hak Kim; Masataka Ichikawa; Tadashi Mio; Michiaki Mishima
Journal:  Jpn J Clin Oncol       Date:  2010-06-03       Impact factor: 3.019

Review 2.  Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.

Authors:  Michael J Eck; Cai-Hong Yun
Journal:  Biochim Biophys Acta       Date:  2009-12-22

3.  Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

Authors:  Rama Krishna Kancha; Nikolas von Bubnoff; Christian Peschel; Justus Duyster
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

4.  EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Authors:  Maria E Arcila; Khedoudja Nafa; Jamie E Chaft; Natasha Rekhtman; Christopher Lau; Boris A Reva; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Mol Cancer Ther       Date:  2013-01-31       Impact factor: 6.261

5.  Predicting the functional impact of protein mutations: application to cancer genomics.

Authors:  Boris Reva; Yevgeniy Antipin; Chris Sander
Journal:  Nucleic Acids Res       Date:  2011-07-03       Impact factor: 16.971
  5 in total
  10 in total

Review 1.  Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.

Authors:  Xiaoli Zhu; Qianming Bai; Yongming Lu; Peng Qi; Jianhui Ding; Jialei Wang; Xiaoyan Zhou
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

Review 2.  Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.

Authors:  Yoshihisa Kobayashi; Tetsuya Mitsudomi
Journal:  Cancer Sci       Date:  2016-08-09       Impact factor: 6.716

3.  Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Authors:  Eri Banno; Yosuke Togashi; Yu Nakamura; Masato Chiba; Yoshihisa Kobayashi; Hidetoshi Hayashi; Masato Terashima; Marco A de Velasco; Kazuko Sakai; Yoshihiko Fujita; Tetsuya Mitsudomi; Kazuto Nishio
Journal:  Cancer Sci       Date:  2016-07-14       Impact factor: 6.716

4.  Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.

Authors:  Deborah A Belchis; Li-Hui Tseng; Thomas Gniadek; Lisa Haley; Parvez Lokhandwala; Peter Illei; Christopher D Gocke; Patrick Forde; Julie Brahmer; Frederic B Askin; James R Eshleman; Ming-Tseh Lin
Journal:  Oncotarget       Date:  2016-07-19

5.  Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.

Authors:  Hua Duan; Yanmei Peng; Huijuan Cui; Yuqin Qiu; Qiang Li; Jingyi Zhang; Wen Shen; Chenyao Sun; Chufan Luo
Journal:  Onco Targets Ther       Date:  2018-04-23       Impact factor: 4.147

Review 6.  Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

Authors:  Peter T Harrison; Simon Vyse; Paul H Huang
Journal:  Semin Cancer Biol       Date:  2019-09-25       Impact factor: 15.707

7.  Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.

Authors:  Lei Lei; Wen-Xian Wang; You-Cai Zhu; Jin-Luan Li; Yong Fang; Hong Wang; Wu Zhuang; Yin-Bin Zhang; Li-Ping Wang; Mei-Yu Fang; Chun-Wei Xu; Xiao-Jia Wang; Tang-Feng Lv; Yong Song
Journal:  Cancer Med       Date:  2019-11-06       Impact factor: 4.452

8.  Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma.

Authors:  Xiaoyu Han; Jun Fan; Yumin Li; Yukun Cao; Jin Gu; Xi Jia; Yuhui Wang; Heshui Shi
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

9.  Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.

Authors:  Dan Chen; Zhengbo Song; Guoping Cheng
Journal:  Onco Targets Ther       Date:  2016-07-08       Impact factor: 4.147

10.  Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.

Authors:  Cuicui Zhang; Li Lin; Ran Zuo; Yajie Wang; Peng Chen
Journal:  Thorac Cancer       Date:  2020-08-09       Impact factor: 3.500
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.